Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471690 | 0.84 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDALOX15MAPK1 | |
| SCHEMBL6087128 | 0.82 | TPH1 (0.34) | ALDH1A1MAPTHPGDSMN1; SMN2MEN1 | |
| SCHEMBL12829055 | 0.80 | MAOB (0.36) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6086817 | 0.79 | HPGD (0.43) | ALDH1A1MAPTHPGDHSD17B10NPSR1 | |
| SCHEMBL2470798 | 0.79 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDALOX15MAPK1 | |
| SCHEMBL675376 | 0.78 | MEN1 (0.35) | ALDH1A1MAPTHPGDALOX15MAPK1 | |
| SCHEMBL6086617 | 0.78 | GRIN1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6088310 | 0.78 | GRIN1 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL6086491 | 0.78 | PDE5A (0.33) | ALDH1A1MAPTHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL7074091 | 0.78 | GRIN1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986651-B1 | USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C | SAMJIN PHARM CO LTD (KR) | 2011-10-05 | — | — | EP | claimed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | claimed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | claimed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-7851479-B2 | Use of pyrimidinedione derivative for preventing or treating hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | SAMJIN PHARM. CO., LTD. (KR) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023764-A1 | Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C | DPYD, UMPS, TYMP | ALDH1A1 186/4885MAPT 4312/4885HPGD 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.